🇺🇸 LY900003 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Haemoglobin Decreased — 2 reports (18.18%)
2. Abdominal Pain — 1 report (9.09%)
3. Acute Coronary Syndrome — 1 report (9.09%)
4. Blood Potassium Abnormal — 1 report (9.09%)
5. Dyspnoea — 1 report (9.09%)
6. Lobar Pneumonia — 1 report (9.09%)
7. Platelet Count Decreased — 1 report (9.09%)
8. Pneumonia — 1 report (9.09%)
9. Shock — 1 report (9.09%)
10. Thrombocytopenia — 1 report (9.09%)

Source database →

Frequently asked questions

Is LY900003 approved in United States?

LY900003 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for LY900003 in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.